<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">231</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2019-18-1-96-103</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hepatosplenic γδ T-cell lymphoma in a 4 years old child</article-title><trans-title-group xml:lang="ru"><trans-title>Случай гепатоспленической γδ Т-клеточной лимфомы у ребенка</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3247-8688</contrib-id><name-alternatives><name xml:lang="en"><surname>Anderzhanova</surname><given-names>L. H.</given-names></name><name xml:lang="ru"><surname>Андержанова</surname><given-names>Л. Х.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Lily H. Anderzhanova - MD, hematology, Department of oncohematology.</p><p>117997, Moscow, Samory Mashela st., 1</p></bio><bio xml:lang="ru"><p>Андержанова Лилия Халитовна - врач-гематолог отделения онкогематологии.</p><p>Москва, ГСП-7, ул. Саморы Машела, 1</p></bio><email>anderliliya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2294-0821</contrib-id><name-alternatives><name xml:lang="en"><surname>Fomynih</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Фоминых</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3664-2876</contrib-id><name-alternatives><name xml:lang="en"><surname>Abramov</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Абрамов</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4779-1896</contrib-id><name-alternatives><name xml:lang="en"><surname>Miakova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Мякова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-04-21" publication-format="electronic"><day>21</day><month>04</month><year>2019</year></pub-date><volume>18</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>96</fpage><lpage>103</lpage><history><date date-type="received" iso-8601-date="2019-04-21"><day>21</day><month>04</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-04-21"><day>21</day><month>04</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/231">https://hemoncim.com/jour/article/view/231</self-uri><abstract xml:lang="en"><p>Hepatosplenic T-cell lymphoma (HSTCL) is a rare and clinically aggressive type of T-cell lymphoma that characterized by proliferation in the liver, spleen and bone marrow. The article presents analytical review of literature and the clinical case of γδ HSTCL in 4 years old child. Patient's parents agreed to use personal dats and photos in research and publications.</p></abstract><trans-abstract xml:lang="ru"><p>Гепатоспленическая Т-клеточная лимфома (ГТКЛ) - редкая, агрессивно протекающая периферическая Т-клеточная лимфома, характеризующаяся пролиферацией злокачественных ав или γδ Т-лимфоцитов в печени, селезенке, костном мозге. В статье представлен анализ литературных данных и разбор клинического случая гепатоспленической γδ Т-клеточной лимфомы у ребенка 4 лет. Родители пациента дали согласие на использование информации о нем, в том числе фотографий, в научных исследованиях и публикациях.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hepatosplenic T-cell lymphoma</kwd><kwd>peripheral T-cell lymphomas</kwd><kwd>hepatosplenomegaly</kwd><kwd>children</kwd><kwd>inflammatory bowel diseases</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гепатоспленическая Т-клеточная лимфома</kwd><kwd>периферические Т-клеточные лимфомы</kwd><kwd>гепатоспленомегалия</kwd><kwd>дети</kwd><kwd>воспалительные заболевания кишечника</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1.	Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016; 127:2375-2390. DOI: https://doi.org/10.1182/blood-2016-01-643569</mixed-citation><mixed-citation xml:lang="ru">Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016; 127:2375-2390. DOI: https://doi.org/10.1182/blood-2016-01-643569</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2.	Gaulard P., Marolleau J.P., Le Couedic J.P., Henni T., Gourdin M.F., Divine M., et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma-delta. Blood 1990; 75 (11): 2213-9.</mixed-citation><mixed-citation xml:lang="ru">Gaulard P., Marolleau J.P., Le Couedic J.P., Henni T., Gourdin M.F., Divine M., et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma-delta. Blood 1990; 75 (11): 2213-9.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3.	Armitage J.O. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol 2017; 92: 706-15.</mixed-citation><mixed-citation xml:lang="ru">Armitage J.O. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol 2017; 92: 706-15.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4.	Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L. A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma Study Group. Blood 1994; 84: 1361-92.</mixed-citation><mixed-citation xml:lang="ru">Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L. A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma Study Group. Blood 1994; 84: 1361-92.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5.	Suarez F., Wlodarska I., Rigal-Hugu-et F., Mempel M., Martin-Garcia N., Farcet J.P. Hepatosplenic alpha-beta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gamma-delta hepatosplen-ic T-cell lymphoma. Am J Surg Pathol 2000; 24: 1027-32.</mixed-citation><mixed-citation xml:lang="ru">Suarez F., Wlodarska I., Rigal-Hugu-et F., Mempel M., Martin-Garcia N., Farcet J.P. Hepatosplenic alpha-beta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gamma-delta hepatosplen-ic T-cell lymphoma. Am J Surg Pathol 2000; 24: 1027-32.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6.	Gaulard P., Jaffe E.S., Krenacs L., Macon W.R. Hepatosplenic T-cell lymphoma. In: Swerdlow S.H, Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2017; 381-2.</mixed-citation><mixed-citation xml:lang="ru">Gaulard P., Jaffe E.S., Krenacs L., Macon W.R. Hepatosplenic T-cell lymphoma. In: Swerdlow S.H, Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2017; 381-2.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7.	Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.</mixed-citation><mixed-citation xml:lang="ru">Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8.	Ferreri A.J., Govi S., Pileri S.A. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol 2012 Aug; 83 (2): 283-92. DOI: 10.1016/j.cri-trevonc.2011.10.001. Epub 2011 Nov 1</mixed-citation><mixed-citation xml:lang="ru">Ferreri A.J., Govi S., Pileri S.A. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol 2012 Aug; 83 (2): 283-92. DOI: 10.1016/j.cri-trevonc.2011.10.001. Epub 2011 Nov 1</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9.	Thai A., Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4: 511-22.</mixed-citation><mixed-citation xml:lang="ru">Thai A., Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4: 511-22.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10.	Kotlgar D.S. A Systematic Review of Factors That Contribute of Hepatosplenic T-cell Lymphoma in Patients with Inflam. Borel Disease.</mixed-citation><mixed-citation xml:lang="ru">Kotlgar D.S. A Systematic Review of Factors That Contribute of Hepatosplenic T-cell Lymphoma in Patients with Inflam. Borel Disease.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11.	Mackey A.C., Green L., Liang L.C., Dinndorf P., Avigan M. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7.</mixed-citation><mixed-citation xml:lang="ru">Mackey A.C., Green L., Liang L.C., Dinndorf P., Avigan M. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12.	Ochenrider M.G., Patterson D.J., Abou-lafia D.M. Hepatosplenic T-cell Lymphoma in a Young Man With Crohn's Disease: Case Report and Literature Review. Clinical Lymphoma, Myeloma &amp; Leukemia 2010; 10 (2): 144-8.</mixed-citation><mixed-citation xml:lang="ru">Ochenrider M.G., Patterson D.J., Abou-lafia D.M. Hepatosplenic T-cell Lymphoma in a Young Man With Crohn's Disease: Case Report and Literature Review. Clinical Lymphoma, Myeloma &amp; Leukemia 2010; 10 (2): 144-8.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13.	Weidmann E. Hepatosplenic T-cell lym- 21. phoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14 (6): 991-7.</mixed-citation><mixed-citation xml:lang="ru">Weidmann E. Hepatosplenic T-cell lym- 21. phoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14 (6): 991-7.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14.	Cooke C.B., Krenacs L., Stetler- 22. Stevenson M., Greiner T.C., Raffeld M., Kingma D.W. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-74.</mixed-citation><mixed-citation xml:lang="ru">Cooke C.B., Krenacs L., Stetler- 22. Stevenson M., Greiner T.C., Raffeld M., Kingma D.W. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-74.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15.	Florena A.M., Tripodo C., Porcasi R., Ingrao S., Fadda M.R., De Cantis S. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. Leuk Lymphoma 2006; 47 (1): 49-57.</mixed-citation><mixed-citation xml:lang="ru">Florena A.M., Tripodo C., Porcasi R., Ingrao S., Fadda M.R., De Cantis S. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. Leuk Lymphoma 2006; 47 (1): 49-57.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16.	Belhadj K., Reyes F., Farcet J.P., Tilly H., Bastard C., Angonin R. Hepatosplenic gamma delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 2003; 102: 4261-9.</mixed-citation><mixed-citation xml:lang="ru">Belhadj K., Reyes F., Farcet J.P., Tilly H., Bastard C., Angonin R. Hepatosplenic gamma delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 2003; 102: 4261-9.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17.	Macon W.R., Levy N.B., Kurtin P.J., Salhany K.E., Elkhalifa M.Y., Casey T.T. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Sur Pathol 26. 2001; 25 (3): 285-96.</mixed-citation><mixed-citation xml:lang="ru">Macon W.R., Levy N.B., Kurtin P.J., Salhany K.E., Elkhalifa M.Y., Casey T.T. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Sur Pathol 26. 2001; 25 (3): 285-96.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18.	Przybylski G.K., Wu H., Macon W.R., Finan J., Leonard D.G., Felgar R.E. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T-cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000; 2 (1): 11-9.</mixed-citation><mixed-citation xml:lang="ru">Przybylski G.K., Wu H., Macon W.R., Finan J., Leonard D.G., Felgar R.E. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T-cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000; 2 (1): 11-9.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19.	Wlodarska I., Martin-Garcia N., Ach-ten R., De Wolf-Peeters C., Pauwels P., Tulliez M. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes, chromosomes &amp; cancer 2002; 33: 243-51.</mixed-citation><mixed-citation xml:lang="ru">Wlodarska I., Martin-Garcia N., Ach-ten R., De Wolf-Peeters C., Pauwels P., Tulliez M. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes, chromosomes &amp; cancer 2002; 33: 243-51.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20.	McKinney M., Moffitt A.B., Gau-lard P., Travert M., De Leval L., Nicolae A. The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discovery 2017; 7 (4): 369-79.</mixed-citation><mixed-citation xml:lang="ru">McKinney M., Moffitt A.B., Gau-lard P., Travert M., De Leval L., Nicolae A. The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discovery 2017; 7 (4): 369-79.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><mixed-citation>Calvaruso M., Gulino A., Buffa S., Guarnotta C., Franco G., Cacciatore M. Challenges and new prospects in hepat-osplenic yS T-cell lymphoma. Leukemia &amp; Lymphoma 2014; 55 (11): 2457-65.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Weidmann E. Hepatosplenic T-cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991-7.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Falchook G.S., Vega F., Dang N.H., Samaniego F., Rodriguez M.A., Cham-plin R.E. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009; 20: 1080-5.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Jaeger G., Bauer F., Brezinschek R., Beham-Schmid C., Mannhalter C., Neu-meister P. Hepatosplenic gammadelta Tcell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008; 19 (5): 1025-6.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Koenecke C., Czeloth N., Bubke A., Schmitz S., Kissenpfennig A., Malis-sen B. Alloantigen-specific de novo-in-duced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009; 39 (11): 3091-6.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Martinet L., Fleury-Cappellesso S., Gadelorge M., Dietrich G., Bourin P., Fournie J.-J. A regulatory cross-talk between gamma delta T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009; 39 (3): 752-62.</mixed-citation></ref></ref-list></back></article>
